Rituximab is active in chronic lymphocytic leukemia (CLL) and may interfere with autoantibodies production in some immune diseases. We report the results of rituximab treatment in 7 patients with CLL-associated symptomatic autoimmune diseases refractory to standard immunosuppressive therapies: warm antibody hemolytic anemia (AHA) 4 patients, cold agglutinin disease (CAD) 1, immune thrombocytopenia (IT) 1, axonal degenerating neuropathy (ADN) 1. Rituximab was given at the dose of 375 mg/m2 per week for 4 weeks. One patient with AHA and one with CAD achieved complete normalization of hemoglobin levels and laboratory signs of haemolysis, with response duration (RD) of 8+ and 38+ months, respectively. In the patient with IT, complete remission was reached after the first week of treatment and RD was 6 months. The patient with ADN achieved a marked neurological improvement after rituximab therapy, with RD of 12 months. Retreatment of both patients with IT and ADN was effective. Rituximab may be an alternative agent for the treatment CLL-associated autoimmune diseases.

Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases / Zaja, F.; Vianelli, N.; Sperotto, A.; Patriarca, F.; Tani, M.; Marin, L.; Tiribelli, M.; Candoni, A.; Baccarani, M.; Fanin, R.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 44:11(2003), pp. 1951-1955. [10.1080/1042819031000119235]

Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases

Candoni A.;
2003

Abstract

Rituximab is active in chronic lymphocytic leukemia (CLL) and may interfere with autoantibodies production in some immune diseases. We report the results of rituximab treatment in 7 patients with CLL-associated symptomatic autoimmune diseases refractory to standard immunosuppressive therapies: warm antibody hemolytic anemia (AHA) 4 patients, cold agglutinin disease (CAD) 1, immune thrombocytopenia (IT) 1, axonal degenerating neuropathy (ADN) 1. Rituximab was given at the dose of 375 mg/m2 per week for 4 weeks. One patient with AHA and one with CAD achieved complete normalization of hemoglobin levels and laboratory signs of haemolysis, with response duration (RD) of 8+ and 38+ months, respectively. In the patient with IT, complete remission was reached after the first week of treatment and RD was 6 months. The patient with ADN achieved a marked neurological improvement after rituximab therapy, with RD of 12 months. Retreatment of both patients with IT and ADN was effective. Rituximab may be an alternative agent for the treatment CLL-associated autoimmune diseases.
2003
44
11
1951
1955
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases / Zaja, F.; Vianelli, N.; Sperotto, A.; Patriarca, F.; Tani, M.; Marin, L.; Tiribelli, M.; Candoni, A.; Baccarani, M.; Fanin, R.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 44:11(2003), pp. 1951-1955. [10.1080/1042819031000119235]
Zaja, F.; Vianelli, N.; Sperotto, A.; Patriarca, F.; Tani, M.; Marin, L.; Tiribelli, M.; Candoni, A.; Baccarani, M.; Fanin, R.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1294108
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 81
  • ???jsp.display-item.citation.isi??? 65
social impact